Here are the Form 4 insider transactions from OneMedNet Corp (ONMD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ONMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONMD filings page.
OneMedNet Corp (ONMD) director and 10% owner Thomas Kosasa purchased 129,758 common shares directly on October 7, 2026, at $5.78 per share. OneMedNet entered into a subscription agreement with Kosasa for a $750,000 investment. His reported direct holdings after the purchase were 1,983,573 shares; no Rule 10b5-1 plan is reported.
OneMedNet Corp’s Chief Medical Officer, director and 10% owner Jeffrey Yu purchased 45,126 common shares on October 9, 2026, through a subscription agreement for a $250,000 investment. The shares were valued at $5.54 per share, based on the issuer’s volume-weighted average price for the 10 trading days immediately before the purchase. Yu directly held 896,840 shares after the purchase. Separately, a trust for his children held 131,197 shares with an independent trustee; Yu said he had no investment control and disclaimed beneficial ownership. No Rule 10b5-1 plan is reported.
OneMedNet Corp (ONMD) Chief Financial Officer and director Robert Lawrence Golden reported direct grants of 35,000 restricted stock units on July 6, 2026, and 10,000 restricted stock units on January 1, 2026. The January award amount reflects the 1-for-10 reverse stock split on September 29, 2026. The July grant vests in installments subject to continued service; the January grant vests in full on December 31, 2026, subject to the Consulting Agreement terms.
Golden also reported direct sales of 8,500 common shares to cover tax obligations upon RSU vesting and settlement: 2,500 shares at $6.6000 per share on September 14, 3,000 at $6.3000 on September 15, and 3,000 at $6.6300 on September 21, 2026. No Rule 10b5-1 plan is reported.
OneMedNet Corp reported that its Chief Executive Officer and director, Aaron Green, was granted 65,000 restricted stock units on July 6, 2026, under its 2022 Equity Incentive Plan. Green sold 5,000 common shares at $7.3920 per share on September 22 and 1,667 at $6.4800 per share on September 24, 2026, to cover tax obligations upon RSU vesting and settlement; no Rule 10b5-1 plan is reported. The share amounts and prices reflect the issuer's 1-for-10 reverse stock split on September 29, 2026.
OneMedNet Corp (ONMD) reported that Jeffrey Yu, a director, Chief Medical Officer and more-than-10% owner, entered into a subscription agreement to purchase 142,857 shares of common stock on September 10, 2026 for a $90,000 investment, valued at a $0.63 volume-weighted average price over the prior 10 trading days. Following this transaction, he holds 8,923,267 shares directly and an additional 1,311,970 shares are held indirectly in a trust for his children with an independent trustee; he disclaims beneficial ownership of the trust shares. No Rule 10b5-1 trading plan is reported.
OneMedNet Corp reported that director and 10% owner Thomas Kosasa purchased 1,449,275 shares of common stock on July 30, 2026. The $1,000,000 investment was made through a subscription agreement, with the shares priced at $0.69 each, based on the volume-weighted average price for the 10 trading days immediately prior to the purchase date. Following the transaction, he directly owns 18,538,150 shares.
OneMedNet Corp Chief Executive Officer Aaron Green reported an open-market purchase of 36,650 shares of the company’s Common Stock. The shares were bought at an average price of $0.5733 per share in a single transaction.
Following this purchase, Green directly holds 1,896,375 shares of OneMedNet Common Stock, indicating that the transaction modestly increased his existing ownership position.
OneMedNet Corp Chief Medical Officer Jeffrey Yu reported a direct open-market purchase of 158,730 shares of Common Stock at $0.63 per share. This reflects a $100,000 investment under a subscription agreement dated June 23, 2026. After this transaction, he directly holds 8,780,410 shares. An additional 1,311,970 shares are held in a trust for his children with an independent trustee, where he has no investment control and disclaims beneficial ownership.
OneMedNet Corp Chief Medical Officer Jeffrey Yu made a substantial open-market purchase of company stock. On June 16, 2026, he bought 172,414 shares of common stock at $0.58 per share under a subscription agreement for a $100,000 investment.
Following this purchase, Yu directly holds 8,621,680 shares of OneMedNet common stock. The filing also reports 1,311,970 shares held indirectly in a trust for his children with an independent trustee, for which he has no investment control and disclaims beneficial ownership.
OneMedNet Corp director and CEO Aaron Green reported open-market purchases of the company’s Common Stock. On June 12, 2026, he bought 36,920 shares at an average price of $0.5581 per share. On June 15, 2026, he bought an additional 18,702 shares at an average price of $0.5396 per share.
After these transactions, Green directly owned 1,859,725 Common Stock shares. A footnote explains that one of the reported prices is a weighted average for multiple trades executed between $0.5463 and $0.5625 per share.
OneMedNet Corp director and 10% owner Thomas Kosasa bought 158,730 shares of common stock at $0.63 per share. The $100,000 investment was made on June 12, 2026 through a subscription agreement, with the share price based on the 10-day volume-weighted average price. Following this purchase, Kosasa directly holds 17,088,874 shares of OneMedNet.
OneMedNet Corp director and 10% owner Thomas Kosasa bought additional common stock. On May 18, 2026, he acquired 268,817 shares of OneMedNet common stock at a reported price of $0.93 per share, increasing his direct holdings to 16,930,144 shares.
The purchase was made through a $250,000 investment in OneMedNet under a subscription agreement, with the shares valued at the volume-weighted average price for the 10 trading days immediately before the purchase date.
OneMedNet Corp director and Chief Medical Officer Jeffrey Yu increased his stake through a sizable cash investment and share grant. On April 1, 2026, he invested $750,000 in a subscription agreement, receiving 903,614 common shares at $0.83 each, and was issued 219,429 shares in lieu of prior cash compensation at the same price. Following these transactions, he directly owns 8,449,266 common shares. An additional 1,311,970 shares are held in a trust with an independent trustee, for which he disclaims beneficial ownership.
OneMedNet Corp director and ten percent owner Thomas Kosasa increased his direct holdings through two stock purchases. On February 6, 2026, he bought 595,238 shares of common stock at $0.84 per share under a $500,000 subscription agreement. On April 23, 2026, he purchased 280,898 shares at $0.89 per share under a $250,000 subscription agreement. These transactions total 876,136 shares and $750,000 of investment, bringing his direct ownership to 16,661,327 common shares after the latest purchase. The purchase prices were based on the volume-weighted average price over the 10 trading days before each purchase date.
OneMedNet Corp insider activity: a director and Chief Medical Officer reported multiple open-market purchases of OneMedNet common stock between December 8, 2023 and January 30, 2024, generally in small increments at prices ranging from about $0.48 to $1.36 per share, some reported as weighted average prices from multiple trades. On January 19, 2024, the insider also received 45,000 restricted stock units (RSUs) as director compensation under the 2022 Equity Incentive Plan for board service in fiscal year 2024; each RSU represents one share of common stock and vested on December 31, 2024. Following these transactions, the insider reported owning 2,507,351 shares directly and 1,311,970 shares indirectly through a trust for children with an independent trustee, for which beneficial ownership is disclaimed.